Cadian Capital Management’s Moderna MRNA Stock Holding History

Cadian Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,000	Closed	-$642K	–	29
2020 Q2	$642K	Buy	+10,000	New	+$548K	0.03%	23

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Cadian Capital Management's MRNA Position: Q3 2020 in Review

Cadian Capital Management sold out of Moderna (MRNA) in Q3 2020, closing a stake of 10,000 shares — an estimated $642K sold.

Cadian Capital Management first reported a position in MRNA in Q2 2020 and held it in 1 quarter. The position peaked at $642K in Q2 2020. 547 funds tracked by Wall St. Rank hold MRNA as of Q3 2020.

Cadian Capital Management reported no remaining Moderna position as of Q3 2020 after selling out during the quarter.
Cadian Capital Management sold 10,000 Moderna shares in Q3 2020, an estimated $642K.
Cadian Capital Management first reported a position in Moderna in Q2 2020 and held it in 1 quarter.
Cadian Capital Management's Moderna position peaked at $642K in Q2 2020.
547 funds tracked by Wall St. Rank held Moderna as of Q3 2020.

Based on Cadian Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.